DYRK1A and diabetes mellitus: In the case of DYRK1A, the search for both naturally occurring and synthetic inhibitors has been extensive given that DYRK1A may be a potential pharmacological target not only in cancer but, also, in neurodegenerative diseases (reviewed in [43]), DS [169,170,171,172] and diabetes (reviewed in [173]).